Related Experiment Video

Updated: Sep 12, 2025

Generation of Human Nasal Epithelial Cell Spheroids for Individualized Cystic Fibrosis Transmembrane Conductance Regulator Study
08:00

Generation of Human Nasal Epithelial Cell Spheroids for Individualized Cystic Fibrosis Transmembrane Conductance Regulator Study

Published on: April 11, 2018

10.8K

Cystic Fibrosis Year in Review 2024

Adrienne P Savant1,2

  • 1Department of Pediatrics, Manning Family Children's, New Orleans, Louisiana, USA.

Pediatric Pulmonology
|August 8, 2025
PubMed

Insights

Advances in cystic fibrosis (CF) care in 2024 include new guidelines for CF transmembrane conductance regulator (CFTR)-Related Metabolic Syndrome/Cystic Fibrosis Screen Positive Inconclusive Diagnosis (CRMS/CFSPID) and updated information on CFTR modulator therapies.

Area of Science:

  • Pulmonology and Genetics
  • Pediatric Care

Background:

  • Cystic Fibrosis (CF) management is evolving with new therapeutic options.
  • The landscape of CF care delivery is shifting, particularly in the post-CFTR modulator era.

Purpose of the Study:

  • To review significant 2024 advances in cystic fibrosis care.
  • To provide high-level information for potential clinical practice changes.

Main Methods:

  • Literature review of 2024 publications relevant to CF care.
  • Synthesis of new guidelines, position papers, and research findings.

Main Results:

  • Publication of crucial guidelines for newborn screening and management of CF transmembrane conductance regulator (CFTR)-Related Metabolic Syndrome/Cystic Fibrosis Screen Positive Inconclusive Diagnosis (CRMS/CFSPID).
  • Development of new position papers addressing care delivery and team composition in the post-CFTR modulator era.
  • Continued research on optimizing growth, nutrition, pulmonary exacerbation treatment, and understanding CFTR modulator side effects (mental health, pregnancy).

Conclusions:

  • 2024 brought key updates in CF newborn screening and CRMS/CFSPID management.
  • The post-CFTR modulator era necessitates updated approaches to care delivery and team structure.
  • Ongoing research addresses treatment burden, side effects, and specific populations within CF care.

Keywords:
CFTR modulatorscystic fibrosisnewborn screeningpulmonary exacerbations

More Related Videos

Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis05:56

Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis

Published on: August 29, 2025

27
Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients07:04

Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients

Published on: February 11, 2017

19.4K

Related Concept Videos

Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
224
Cystic Fibrosis: Pathogenesis01:23

Cystic Fibrosis: Pathogenesis

Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
361
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
128
Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies01:27

Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies

Assessing and diagnosing Chronic Obstructive Pulmonary Disease (COPD) involves a detailed approach that includes a comprehensive review of medical history, physical examination, and a variety of diagnostic tests. This thorough evaluation is essential to ensure an accurate diagnosis and guide effective management strategies.
Medical History
2.6K
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
2.7K